Careside Inc (NASDAQ:CASI) Stock Sentiment Increases

July 14, 2018 - By Margaret Downey

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Logo

Sentiment for Careside Inc (NASDAQ:CASI)

Careside Inc (NASDAQ:CASI) institutional sentiment increased to 2 in 2018 Q1. Its up 0.10, from 1.9 in 2017Q4. The ratio has increased, as 22 investment managers increased or opened new holdings, while 11 sold and reduced positions in Careside Inc. The investment managers in our partner’s database now have: 4.96 million shares, up from 3.56 million shares in 2017Q4. Also, the number of investment managers holding Careside Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 1 Reduced: 10 Increased: 12 New Position: 10.

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. The company has market cap of $628.86 million. The Company’s lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. It currently has negative earnings. The companyÂ’s late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkinÂ’s lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkinÂ’s lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.

The stock decreased 3.18% or $0.24 during the last trading session, reaching $7.3. About 278,153 shares traded. CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has risen 585.86% since July 14, 2017 and is uptrending. It has outperformed by 573.29% the S&P500.

Analysts await CASI Pharmaceuticals, Inc. (NASDAQ:CASI) to report earnings on August, 13. They expect $-0.07 earnings per share, down 75.00 % or $0.03 from last year’s $-0.04 per share. After $-0.05 actual earnings per share reported by CASI Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 40.00 % negative EPS growth.

Wellington Shields & Co. Llc holds 0.79% of its portfolio in CASI Pharmaceuticals, Inc. for 625,118 shares. Wellington Shields Capital Management Llc owns 790,256 shares or 0.5% of their US portfolio. Moreover, Penobscot Investment Management Company Inc. has 0.03% invested in the company for 27,000 shares. The New York-based Alpine Global Management Llc has invested 0.01% in the stock. Moors & Cabot Inc., a Massachusetts-based fund reported 22,935 shares.

More notable recent CASI Pharmaceuticals, Inc. (NASDAQ:CASI) news were published by: which released: “Benzinga’s Daily Biotech Pulse: Realm Therapeutics To List On Nasdaq, CASI Pharma Added To Russell 2000 Index” on July 05, 2018, also with their article: “Here’s Why CASI Pharmaceuticals Rose as Much as 31.6% Today” published on June 21, 2018, published: “Mid-Morning Market Update: Markets Open Lower; Kroger Earnings Beat Expectations” on June 21, 2018. More interesting news about CASI Pharmaceuticals, Inc. (NASDAQ:CASI) were released by: and their article: “Mid-Day Market Update: Dow Down Over 150 Points; CASI Pharmaceuticals Shares Spike Higher” published on June 21, 2018 as well as‘s news article titled: “Report: Exploring Fundamental Drivers Behind Cabot Oil & Gas, Chesapeake Lodging Trust, CASI Pharmaceuticals …” with publication date: June 25, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: